Breaking News Instant updates and real-time market news.

FCX

Freeport McMoRan

$13.86

-0.08 (-0.57%)

, QCOM

Qualcomm

$51.48

0.47 (0.92%)

07:35
09/15/17
09/15
07:35
09/15/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Freeport McMoRan (FCX), Qualcomm (QCOM), Delta Air Lines (DAL), Transocean (RIG), Tenet (THC), CSX (CSX), Hess Corp. (HES), Juno Therapeutics (JUNO), Oasis Petroleum (OAS), and Mallinckrodt (MNK).

FCX

Freeport McMoRan

$13.86

-0.08 (-0.57%)

QCOM

Qualcomm

$51.48

0.47 (0.92%)

DAL

Delta Air Lines

$48.27

-0.71 (-1.45%)

RIG

Transocean

$9.22

0.01 (0.11%)

THC

Tenet

$17.16

0.92 (5.67%)

CSX

CSX

$52.08

0.01 (0.02%)

HES

Hess Corp.

$42.00

0.12 (0.29%)

JUNO

Juno Therapeutics

$44.61

-0.71 (-1.57%)

OAS

Oasis Petroleum

$8.27

0.11 (1.35%)

MNK

Mallinckrodt

$35.21

-0.43 (-1.21%)

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 29

    Oct

  • 30

    Oct

FCX Freeport McMoRan
$13.86

-0.08 (-0.57%)

07/12/17
07/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Monsanto (MON) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying Bayer's (BAYRY) all-cash offer appears on track for year-end. The analyst views the deal failing as a "low-probability scenario" and keeps a $128 price target for the shares. 2. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 3. Kimberly-Clark (KMB) downgraded to Sell from Neutral at UBS with analyst Stephen Powers saying the stock's 11% rise year-to-date is not based on fundamentals but news flow of consolidation in the Household Products sector. 4. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at Bernstein with analyst David Beckel citing his belief that "demographic shifts and a stagnating economy" will prevent demand for the company's motorcycles from growing in the U.S. for the next five years. 5. IMAX (IMAX) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying positive catalysts "might take some time to develop." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/17
BREN
07/12/17
DOWNGRADE
BREN
Sell
Freeport McMoRan downgraded to Sell from Hold at Berenberg
Berenberg analyst Fawzi Hanano downgraded Freeport McMoRan to Sell.
09/07/17
MACQ
09/07/17
INITIATION
Target $16
MACQ
Neutral
Freeport McMoRan initiated with a Neutral at Macquarie
Macquarie analyst David Lipschitz initiated Freeport McMoRan with a Neutral and a $16 price target. The analyst believes the copper market has tightened but feels it is still oversupplied in the medium term.
04/27/17
DBAB
04/27/17
NO CHANGE
Target $14
DBAB
Hold
Freeport McMoRan risk/reward not yet favorable, says Deutsche Bank
Deutsche Bank analyst Chris Terry says Freeport McMoRan's Q1 results were impacted by strikes, weather and a host of issues at Grasberg. The analyst does not see an attractive risk/reward opportunity with the key operating terms at Grasberg over the medium-to-long term remaining unresolved. He keeps a Hold rating on the shares with a $14 price target.
QCOM Qualcomm
$51.48

0.47 (0.92%)

07/31/17
WELS
07/31/17
NO CHANGE
WELS
Wells Fargo downgrades Semiconductor sector to Market Weight
Wells Fargo analyst David Wong downgraded the Semiconductor sector to Market Weight from Overweight. Recent earnings reports from chip companies suggest that year-over-year growth will likely plateau or perhaps even decelerate over the next few months, Wong tells investors in a research note. He believes many chip stocks now have "elevated multiples" off calendar 2018 earnings estimates. Wong still sees good investment opportunities in some specific stocks, however, and reiterates Outperform ratings on Intel (INTC), Qualcomm (QCOM), Micron (MU), AMD (AMD), Skyworks (SWKS) and Microsemi (MSCC).
08/07/17
MSCO
08/07/17
NO CHANGE
Target $117.5
MSCO
Equal Weight
NXP Semiconductors target raised above deal price to $117 at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach believes NXP Semiconductors (NXPI) shareholders "have the upper hand" in seeking to push for a higher takeout price from Qualcomm (QCOM), while also thinking a higher bid would be "inconsequential" to Qualcomm's balance sheet and deal accretion. The analyst, who sees momentum building for a higher deal price and a "hard time believing" Qualcomm would walk away rather than raise the price and get a deal done, raised his price target on NXP to $117.50 from $110. He keeps an Equal Weight rating on NXP shares.
08/09/17
BNCH
08/09/17
NO CHANGE
BNCH
Buy
CEVA could be pressured by latest in Qualcomm-Apple fight, says Benchmark
Benchmark analyst Gary Mobley noted that Qualcomm (QCOM) announced that the ITC has commenced an investigation into Apple's (AAPL) use of certain mobile devices, radio frequency and processing components" as the companies continue their legal fight over disputed royalties. Intel (INTC) and Qualcomm currently split the iPhone 7 thin modem business and it is expected they'll also evenly split the iPhone 8 business, said Mobley, who noted that CEVA (CEVA) could lose $2M-$2.5M in annual royalties if the Intel-based phones are banned for U.S. import. He keeps a Buy rating on CEVA shares, which are down fractionally in early trading.
08/30/17
BARD
08/30/17
NO CHANGE
Target $10
BARD
Outperform
Baird still believes Himax has multiple engagements for 3D cameras
Baird analyst Tristan Gerra notes that Himax (HMIX) and Qualcomm (QCOM) announced a collaboration for a 3D depth sensing camera system to enable computer vision capabilities, notably for use in smartphones. The analyst continues to believe Himax has multiple engagements for 3D cameras in smartphones starting to ramp next year, and views 3D cameras as a critical new, high-ASP component ramp in smartphones over the next few years. Additionally, Gerra points out that Apple (AAPL) may emulate multiple smartphone OEMs to adopt 3D Sensing starting next year. Many smartphone OEMs will require a turnkey 3D camera solution, which Himax/Qualcomm are best positioned to supply, he said. The analyst reiterates an Outperform rating and $10 price target on Himax shares.
DAL Delta Air Lines
$48.27

-0.71 (-1.45%)

09/06/17
IMPC
09/06/17
NO CHANGE
Target $50
IMPC
In-Line
Delta Air Lines price target lowered to $50 from $54 at Imperial Capital
Imperial Capital analyst Michael Derchin lowered his price target for Delta Air Lines to $50 after the company indicated Q3 system PRASM is likely to be lower than initially anticipated. The analyst expects close-in yields to remain weak through FY17 and keeps an In-Line rating on the shares.
08/18/17
WOLF
08/18/17
UPGRADE
WOLF
Outperform
Delta Air Lines upgraded to Outperform from Peer Perform at Wolfe Research
08/18/17
08/18/17
UPGRADE
Target $62

Outperform
Follow-up: Delta Air Lines upgraded to Outperform on valuation at Wolfe Research
As previously reported, Wolfe Research upgraded Delta Air Lines to Outperform from Peer Perform with a $62 price target. The firm views the recent pullback in shares as attractive and thinks reset margin targets in May are more realistic and achievable.
09/06/17
DBAB
09/06/17
NO CHANGE
Target $42
DBAB
Buy
Deutsche cuts price targets for Spirit Airlines, Delta Air Lines
Following the September quarter updates, Deutsche Bank analyst Michael Linenberg lowered his price target for Spirit Airlines (SAVE) to $42 from $54 and for Delta Air Lines (DAL) to $59 from $62. The analyst cites fuel and pricing pressures but keeps Buy ratings on both names.
RIG Transocean
$9.22

0.01 (0.11%)

08/31/17
08/31/17
UPGRADE
Target $12

Overweight
Transocean upgraded to Overweight at Capital One
As previously reported, Capital One upgraded Transocean to Overweight from Equalweight with a $12 price target. Analyst Joseph Gibney said the group is exhibiting some modest "green shoots" and sees upside to Transocean on a relative basis even in a long/measured recovery and some semblance of contracting pickup.
08/31/17
08/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FMC Corporation (FMC) upgraded to Buy from Underperform at BofA/Merrill with analyst Steve Byrne double upgrading FMC following survey results that indicate ag sales are likely to increase 1-3% rather than decline 1-3%, as previously expected. 2. Owens Corning (OC) upgraded to Outperform from Market Perform at Wells Fargo with analyst Stephen East saying he sees an "inexpensive valuation" versus peers and has increased comfort in Owens' ability to achieve or surpass this year's targets. Hurricane Harvey is a boost to the company's roofing business, but its insulation replacement "may be the bigger winner," East tells investors. 3. ChannelAdvisor (ECOM) upgraded to Overweight from Equal-Weight at First Analysis with analyst Lawrence Berlin citing increased confidence in the company's ability to accelerate growth and hit its mid-teen growth targets after meeting with management. 4. Abercrombie & Fitch (ANF) upgraded to Sector Perform from Underperform at RBC Capital with analyst Brian Tunick saying a return to profitability in the second half of 2017 is more likely following Q2 results that suggest that turnaround efforts are yielding results faster than anticipated. 5. Transocean (RIG) upgraded to Overweight from Equalweight at Capital One with analyst Joseph Gibney saying the group is exhibiting some modest "green shoots" and sees upside to Transocean on a relative basis even in a long/measured recovery and some semblance of contracting pickup. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/17
CLKS
09/01/17
UPGRADE
CLKS
Buy
Transocean upgraded to Buy from Neutral at Clarksons Platou
08/31/17
SOCO
08/31/17
UPGRADE
SOCO
Overweight
Transocean upgraded to Overweight from Equalweight at Capital One
THC Tenet
$17.16

0.92 (5.67%)

09/14/17
DBAB
09/14/17
NO CHANGE
Target $24
DBAB
Buy
Deutsche sees wide range of potential takeout values for Tenet
Deutsche Bank analyst Chris Rigg believes Tenet Healthcare's (THC) leverage makes for an "extremely wide" range of potential buyout prices. After the Wall Street Journal reported that the company is exploring strategic options including a possible sale, Rigg pegs $21-$41 per share as the potential buyout range. Also difficult is determining who would actually be interested and capable of buying Tenet, Rigg tells investors in a research note. HCA Holdings (HCA) has the financial wherewithal to do a deal, but the companies have significant overlap which could bring antitrust issues, the analyst contends. He sees private equity or an existing private equity-backed hospital chain as making more sense. Rigg has a Buy rating on Tenet with a $24 price target.
09/14/17
RBCM
09/14/17
NO CHANGE
RBCM
Tenet unlikely to be acquired, says RBC Capital
After The Wall Street Journal reported that Tenet (THC) hired advisors to purse strategic options, RBC Capital analyst Frank Morgan says that all of Tenet probably won't be acquired, given its "significant" debt levels. He says that the company's ambulatory unit is the most likely part of the company to be sold or spun off. The analyst says that HCA (HCA) could be "interested" in some of Tenet's markets, but he does not believe that it wants to buy all of Tenet's hospitals. The analyst does not expect any deals made by Tenet to cause its share price to increase unless it manages to sell its hospitals for rates above their current market value. Morgan keeps a Sector Perform rating on the stock.
09/14/17
KEYB
09/14/17
NO CHANGE
KEYB
Tenet unlikely to find buyer for whole company, says KeyBanc
KeyBanc analyst Jason Gurda notes that Bloomberg is reporting that Tenet has hired advisers to explore strategic alternatives, including a potential sale. The analyst believes it is unlikely it will find a buyer for the whole company due to its high level of debt and the likely lack of interest from potential strategic buyers. However, Gurda does believe that Tenet could expand its effort to divest individual hospitals and/or its Conifer subsidiary at multiples that would be accretive to where the shares are currently trading and would accelerate de-leveraging. But it is not clear at the moment how far management is willing to go in breaking up the business, he adds.
09/14/17
RHCO
09/14/17
NO CHANGE
RHCO
'Potential public suitors' for Tenet 'limited,' says SunTrust
SunTrust analyst David MacDonald says that "potential public suitors" for Tenet are "limited," while its free cash flow "remains sluggish." However, the analyst says that the company's assets are "intriguing," as its non-hospital assets are being undervalued by the market. He keeps a $16 price target and a Hold rating on the shares.
CSX CSX
$52.08

0.01 (0.02%)

09/05/17
OPCO
09/05/17
NO CHANGE
OPCO
Oppenheimer discontinuing research coverage of CSX Corporation
Oppenheimer is discontinuing research coverage of CSX Corporation, previously rated Perform. The decision is unrelated to any awareness on its part of any material change in the fundamental condition of the company.
09/07/17
RBCM
09/07/17
NO CHANGE
RBCM
CSX outlook remains attractive despite guidance cut, says RBC Capital
After CSX lowered its full-year EPS guidance because of disruptions it is facing as it implements its new business model, RBC Capital analyst Walter Spracklin "suggests that investors look through the disruption" and the guidance cut. He continues to expect the company to significantly lower its structural costs, and he thinks that it has a "compelling long-term efficiency upside." Spracklin reiterates an Outperform rating on the stock.
09/06/17
SPHN
09/06/17
NO CHANGE
Target $61
SPHN
Overweight
CSX guidance revision not a surprise, says Stephens
Stephens analyst Justin Long nots that CSX just issued a press release revising its 2017 OR and EPS guidance due to various operating challenges in July and August. On the positive side, CSX reiterated its 2017 guidance for free cash flow, service metrics are returning to normal and many of the operational challenges are behind them, the analyst notes. Long says this guidance revision does not come as a major surprise given the company's well publicized operational challenges in Q3. He reiterates an Overweight rating and $61 price target on the shares.
09/07/17
SUSQ
09/07/17
NO CHANGE
Target $59
SUSQ
Positive
CSX update suggests sequential improvements, says Susquehanna
Susquehanna analyst Bascome Majors said he remains new money buyers of CSX shares following management's update, which included a lowered earnings outlook. He said they suggested the lowered outlook was due to temporary issues rather than structural ones and showed a constructive view toward sequential service improvement and long-term financial outcomes ahead of their October investor day. Major reiterated his Positive rating and lowered his price target to $59 from $63 on CSX shares.
HES Hess Corp.
$42.00

0.12 (0.29%)

09/14/17
09/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hertz (HTZ) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Adam Jonas citing the doubling of shares over the last three months and raised its price target to $14 from $12. 2. New Oriental Education (EDU) downgraded to Underweight from Neutral at JPMorgan with analyst Leon Chik saying the downgrade is "purely a valuation call." 3. McKesson (MCK) and AmerisourceBergen (ABC) were downgraded to Equal Weight from Overweight at Morgan Stanley. 4. Apache (APA) and Imperial Oil (IMO) were downgraded to Underweight from Neutral at JPMorgan, while Hess Corp. (HES) was downgraded to Neutral from Overweight. 5. Ryanair (RYAAY) downgraded to Reduce from Hold at HSBC with analyst Andrew Lobbenberg citing the ECJ ruling against the company's practice of employing flight crew on Irish labor contracts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/17
JPMS
09/14/17
DOWNGRADE
Target $45
JPMS
Neutral
Hess Corp. downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Phil Gresh downgraded Hess Corp. to Neutral and lowered his price target for the shares to $45 from $52. The analyst highlights the company's "persistent" spending gap and "premium" valuation.
07/17/17
WOLF
07/17/17
DOWNGRADE
WOLF
Peer Perform
Hess Corp. downgraded to Peer Perform from Outperform at Wolfe Research
06/27/17
06/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Impinj (PI) was downgraded to Sector Weight from Overweight by Pacific Crest analyst Brad Erickson based on valuation. 2. Mizuho analyst Haendel St. Juste downgraded Store Capital (STOR) to Neutral from Buy citing fair valuation following recent strength driven by Berkshire Hathaway's (BRK.A) investment. 3. Camtek (CAMT) was downgraded to Hold from Buy by Needham analyst Y. Edwin Mok, as he expects to see some deceleration as the PCB business normalizes and he believes large orders for back-end semi inspections are already reflected in the stock after its recent run-up. 4. Nomura Instinet analyst Dan Dolev downgraded Cintas (CTAS) to Neutral from Buy after lowering his FY18 uniform rental organic growth forecasts to 5% from 7%. 5. Atlantic Equities analyst Barry MacCarthy downgraded Hess Corp. (HES) and Schlumberger (SLB), both to Neutral from Overweight, given his view of the limited prospects for an oil price rebound. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JUNO Juno Therapeutics
$44.61

-0.71 (-1.57%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Juno Therapeutics initiated with an Overweight at Barclays
Barclays initiated Juno with an Overweight rating and a $55 price target, citing Juno's JCAR017 showing promising data with "a potentially better safety profile compared to the KITE/NVS programs," as well as Juno's pipeline having long-term upside.
09/05/17
FBCO
09/05/17
NO CHANGE
FBCO
Outperform
No read through to Gilead, Kite from Cellectis clinical hold, says Credit Suisse
Credit Suisse analyst Alethia Young said the safety issues that Cellectis (CLLS) is encountering, and which prompted a clinical hold be placed on the company's allogenic CAR-T drug, UCART123, could be to some degree related to the company's platform. She adds that CRS, which led to a death in Cellectis' BPDCN study, is a known issue with CAR-T technologies and cases have been seen in Juno (JUNO) and Kite's (KITE) programs as well. The analyst, who doesn't think there is a read through to Kite and Gilead (GILD) from the Cellectis news and remains confident Kite will receive approval later this fall and launch Axi-Cel, keeps an Outpeform rating on Gilead shares.
08/31/17
STPT
08/31/17
DOWNGRADE
STPT
Reduce
Standpoint downgrades Juno after 50% rally in two weeks
Standpoint Research analyst Ronnie Moas downgraded Juno Therapeutics (JUNO) to Reduce from Buy noting that the shares are up more than 50% in the past two weeks. Despite Juno being a takeover target following Kite Pharma's (KITE) agreement this week to be sold to Gilead Sciences (GILD), positions should be trimmed at current share levels, Moas writes in an email. The analyst points out that Juno's market capitalization is over $4B even though no earnings are being generated. The stock in early trading is up 5%, or $1.98, to 42.27.
08/31/17
STPT
08/31/17
DOWNGRADE
STPT
Reduce
Juno Therapeutics downgraded to Reduce from Buy at Standpoint Research
OAS Oasis Petroleum
$8.27

0.11 (1.35%)

07/18/17
WILL
07/18/17
UPGRADE
WILL
Buy
Oasis Petroleum upgraded to Buy from Hold at Williams Capital
07/19/17
BOFA
07/19/17
INITIATION
Target $9
BOFA
Oasis Petroleum reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Asit Sen reinstated Oasis Petroleum with a Neutral and a $9 price target.
08/29/17
JEFF
08/29/17
NO CHANGE
Target $25
JEFF
Buy
Jefferies cuts oil forecast, Exploration & Production price targets
Jefferies lowered its Brent estimate to $57 per barrel from $64 in 2018, to $60 from $67 in 2019, and to $65 from $70 in 2020. The market appears to be adequately supplied in the near term, but depleting proved developed reserves and shrinking spare capacity should support rising longer-term price assumption, analyst Michael Hsu tells investors in a research note. To reflect the reduced forecast, the analyst cut his price targets for names in the Exploration & Production space. Target cuts include Buy-rated Carrizo Oil & Gas (CRZO) to $25 from $32, Buy-rated Continental Resources (CLR) to $42 from $52, Buy-rated Newfield Exploration (NFX) to $40 from $46, Buy-rated Noble Energy (NBL) to $32 from $36, Buy-rated Oasis Petroleum (OAS) to $13 from $16, Buy-rated Pioneer Natural Resources (PXD) to $171 from $192 and Buy-rated Range Resources (RRC) to $36 from $37.
07/18/17
DBAB
07/18/17
DOWNGRADE
Target $11
DBAB
Hold
Oasis Petroleum downgraded to Hold at Deutsche Bank
Deutsche Bank analyst Ryan Todd downgraded Oasis Petroleum to Hold from Buy and lowered his price target for the shares to $11 from $18. The analyst sees a lack of near-term positive catalysts and has concerns over the company's longer term growth plans in a challenged commodity environment.
MNK Mallinckrodt
$35.21

-0.43 (-1.21%)

09/13/17
MZHO
09/13/17
DOWNGRADE
Target $40
MZHO
Neutral
Mallinckrodt downgraded to Neutral on competitive headwinds at Mizuho
As previously reported, Mizuho downgraded Mallinckrodt (MNK) to Neutral from Buy and slashed its price target to $40 from $70. Following the unexpectedly negative Inomax District Court decision. Analyst Irina Koffler said Mallinckrodt consists of a gradually declining generics portfolio, and a "basket" of branded assets that face some degree of competition and downside risks. Koffler lowered his Inomax forecast to reflect a second market entrant and sees risk to Arthar from any positive progress by competitor ANI Pharmaceuticals (ANIP).
09/15/17
PIPR
09/15/17
NO CHANGE
Target $67
PIPR
Overweight
Mallinckrodt shares can recover with debt pay down, says Piper Jaffray
Shares of Mallinckrodt (MNK) are trading at all-time lows following a federal district court's decision in favor of Praxair (PX) over generic Inomax, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the stock's valuation multiples can recover provided that Mallinckrodt takes a more aggressive approach to debt pay down and continues to make targeted investment in its pipeline. Share buybacks are not the answer, the analyst contends. Amsellem reduced his price target for the shares to $67 from $70 and keeps an Overweight rating on the name.
09/14/17
DBAB
09/14/17
NO CHANGE
Target $45
DBAB
Buy
Mallinckrodt price target lowered to $45 from $56 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert lowered his price target for Mallinckrodt (MNK) shares to $45 citing the recent negative ruling on Inomax. The analyst now assumes a "modest" generic impact to Inomax beginning in 2019. Gilbert believes his new target could prove overly conservative if Mallinckrodt wins on appeal, holds on to more share versus Praxair (PX), or can significantly reduce operating expenses. He admits, though, that "more pessimistic scenarios are also possible, in theory." Gilbert keeps a Buy rating on Mallinckrodt while pointing out the shares "could be stuck in a rut for a period" on the court ruling and lack of near-term catalysts.
09/13/17
09/13/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ON Semiconductor (ON) downgraded to Neutral from Buy at Goldman Sachs with analyst Mark Delaney citing the stock's relative outperformance and lack of catalysts over the next year. 2. Nordstrom (JWN) downgraded to Hold from Accumulate at Gordon Haskett. 3. Mallinckrodt (MNK) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying Mallinckrodt consists of a gradually declining generics portfolio, and a "basket" of branded assets that face some degree of competition and downside risks. 4. Whiting Petroleum (WLL) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Drew Venker citing weak risk-reward relative to peers. 5. GasLog (GLOG) downgraded to Hold from Buy at DNB Markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AGN

Allergan

$215.00

-6.54 (-2.95%)

05:21
09/20/17
09/20
05:21
09/20/17
05:21
Recommendations
Allergan analyst commentary  »

Allergan pipeline largely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TRVG

trivago

$10.99

-0.11 (-0.99%)

05:15
09/20/17
09/20
05:15
09/20/17
05:15
Recommendations
trivago analyst commentary  »

trivago price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

05:12
09/20/17
09/20
05:12
09/20/17
05:12
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$38.97

-0.41 (-1.04%)

05:10
09/20/17
09/20
05:10
09/20/17
05:10
Recommendations
Acceleron analyst commentary  »

Acceleron price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

ICPT

Intercept

$96.20

0.45 (0.47%)

05:01
09/20/17
09/20
05:01
09/20/17
05:01
Recommendations
Intercept analyst commentary  »

Intercept recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

04:57
09/20/17
09/20
04:57
09/20/17
04:57
Downgrade
Yahoo Japan rating change  »

Yahoo Japan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$19.25

1.4 (7.84%)

04:56
09/20/17
09/20
04:56
09/20/17
04:56
Initiation
Epizyme initiated  »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

CSGP

CoStar Group

$280.60

3.97 (1.44%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
CoStar Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

YEXT

Yext

$12.99

-0.27 (-2.04%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Yext management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FCFS

First Cash Financial

$60.65

0.65 (1.08%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
First Cash Financial management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

VNRX

VolitionRx

$2.75

0.07 (2.61%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
VolitionRx management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Citigroup to hold a conference »

2017 SMID and Travel…

SRCL

Stericycle

$70.19

-0.81 (-1.14%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Stericycle management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 27

    Sep

FIVN

Five9

$22.17

0.31 (1.42%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Five9 management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

GMS

GMS Inc.

$33.50

-0.38 (-1.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
GMS Inc. management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

HRTG

Heritage Insurance

$11.83

-0.72 (-5.74%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Heritage Insurance management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

HZNP

Horizon Pharma

$12.10

0.26 (2.20%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Horizon Pharma management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

OHI

Omega Healthcare

$32.53

-0.12 (-0.37%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Omega Healthcare management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MZDAF

Mazda

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Mazda management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

SFS

Smart & Final Stores

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Smart & Final Stores management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SRCI

SRC Energy

$8.18

0.16 (2.00%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
SRC Energy management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 25

    Sep

  • 16

    May

AITB

AIT Therapeutics

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
AIT Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

ARLP

Alliance Resource Partners

$18.90

-0.05 (-0.26%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Alliance Resource Partners management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

EMR

Emerson

$63.21

0.22 (0.35%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Emerson management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

SCSC

Scansource

$40.70

-0.05 (-0.12%)

04:55
09/20/17
09/20
04:55
09/20/17
04:55
Conference/Events
Scansource management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.